Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European journal of internal medicine

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejim.2015.05.001PMID 26049917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• COPD symptoms in the morning: impact, evaluation and management

  2013cited by this paper
• cAMP regulation of airway smooth muscle function.

  2013cited by this paper
• Assessing and accessing the small airways; implications for asthma management.

  2013cited by this paper
• Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.

  2013cited by this paper
• Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis

  2013cited by this paper
• Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses

  2013cited by this paper
• β2-agonist therapy in lung disease.

  2013cited by this paper
• Novel cAMP signalling paradigms: therapeutic implications for airway disease

  2012cited by this paper
• Pharmacology and Therapeutics of Bronchodilators

  2012cited by this paper
• Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis

  2012cited by this paper
• Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease

  2012cited by this paper
• Corticosteroid insensitivity is reversed by formoterol via phosphoinositide‐3‐kinase inhibition

  2012cited by this paper
• Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects.

  2012cited by this paper
• Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.

  2011cited by this paper
• How Can 1 + 1 = 3? β2-Adrenergic and Glucocorticoid Receptor Agonist Synergism in Obstructive Airway Diseases

  2011cited by this paper
• Towards the Grade of Recommendations, Assessment, Development and Evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research.

  2011cited by this paper
• TGFβ-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects.

  2011cited by this paper
• Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.

  2011cited by this paper
• β2‐adrenoceptor agonists: current and future direction

  2011cited by this paper
• The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts

  2011cited by this paper
• Budesonide Prevents Cytokine-Induced Decrease of the Relaxant Responses to Formoterol and Terbutaline, but Not to Salmeterol, in Mouse Trachea

  2010cited by this paper
• Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma.

  2010cited by this paper
• Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus

  2009cited by this paper
• The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial

  2009cited by this paper
• Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

  2009cited by this paper
• A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management

  2009cited by this paper
• Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

  2008cited by this paper
• Methodological issues in therapeutic trials of COPD

  2008cited by this paper
• The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis.

  2008cited by this paper
• Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered‐Dose Inhaler in Patients With Asthma and COPD

  2008cited by this paper
• Long-Acting β2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells

  2008cited by this paper
• Inhibition of human airway smooth muscle cell proliferation by beta 2-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement.

  2008cited by this paper
• Global strategy for asthma management and prevention: GINA executive summary

  2008cited by this paper
• Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells.

  2008cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

  2007cited by this paper
• Scientific rationale for using a single inhaler for asthma control

  2007cited by this paper
• Anti-inflammatory activity of β2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor

  2007influential reference
• Cooperative Inhibitory Effects of Budesonide and Formoterol on Eosinophil Superoxide Production Stimulated by Bronchial Epithelial Cell Conditioned Medium

  2007cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease

  2007cited by this paper
• Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes.

  2006cited by this paper
• Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol.

  2006cited by this paper
• Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells.

  2006cited by this paper
• Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.

  2005cited by this paper
• Molecular mechanisms of beta2-adrenergic receptor function and regulation.

  2005cited by this paper
• Molecular Mechanisms of β2-Adrenergic Receptor Function and Regulation

  2005cited by this paper
• Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.

  2005cited by this paper
• Differential Effects of Short-Acting β2-Agonists on Human Granulocyte Functions

  2005cited by this paper
• Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.

  2004cited by this paper
• Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

  2004cited by this paper
• Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

  2003cited by this paper
• Effects of beta2-agonists on resident and infiltrating inflammatory cells.

  2002cited by this paper
• Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling.

  2002cited by this paper
• Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts

  2002cited by this paper
• Pharmacological similarities and differences between beta2-agonists.

  2001influential reference
• Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells.

  2001cited by this paper
• Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression.

  2001cited by this paper
• Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.

  2000cited by this paper
• Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle.

  2000cited by this paper
• Delayed eosinophil apoptosis in asthma.

  2000cited by this paper
• Synergistic Inhibition by β2-Agonists and Corticosteroids on Tumor Necrosis Factor- α –Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells

  2000cited by this paper
• Effect of β agonists on inflammatory cells

  1999cited by this paper
• Effect of beta-agonists on inflammatory cells.

  1999cited by this paper
• The interrelationship of sputum inflammatory markers in patients with chronic bronchitis.

  1999cited by this paper
• Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells*

  1999cited by this paper
• Differential effects of salbutamol and salmeterol on human eosinophil responses.

  1998cited by this paper
• Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease.

  1998cited by this paper
• Effects of Some Anti-Asthma Drugs on Human Eosinophil Superoxide Anions Release and Degranulation

  1998cited by this paper
• The effect of salmeterol on human eosinophils is both stimulus- and response-dependent.

  1997cited by this paper
• Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

  1997cited by this paper
• Differential Effects of Salbutamol and Salmeterol on Human Eosinophil Responses

  1997cited by this paper
• Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A.

  1997cited by this paper
• Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.

  1997cited by this paper
• Inflammatory cells in the bronchial glands of smokers with chronic bronchitis.

  1997cited by this paper
• Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A

  1997cited by this paper
• Functional and binding characteristics of long-acting beta 2-agonists in lung and heart.

  1996cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• Why are long-acting beta-adrenoceptor agonists long-acting?

  1994cited by this paper
• Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus.

  1994cited by this paper
• Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.

  1993cited by this paper
• Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils.

  1993cited by this paper
• Effect of formoterol on superoxide anion generation from bronchoalveolar lavage cells after antigen challenge in guinea pigs.

  1993cited by this paper
• The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro.

  1992cited by this paper
• Bronchodilator intake and plasma levels on admission for severe acute asthma.

  1992cited by this paper
• On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration.

  1989cited by this paper
• Mechanosensitive and beta-adrenergic control of the ciliary beat frequency of mammalian respiratory tract cells in culture.

  1989cited by this paper
• Beta-adrenoceptor function in asthmatic bronchial smooth muscle.

  1988cited by this paper
• Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte beta-adrenergic receptors.

  1987cited by this paper
• beta-Adrenergic stimulation of respiratory ciliary activity.

  1980cited by this paper

• Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials

  2024cites this paper
• Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.

  2023cites this paper
• Comparative study of an asthmatic patient on using different drugs and therapies

  2023cites this paper
• Emerging Treatments for COPD: Evidence to Date on Revefenacin

  2019cites this paper
• The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis

  2019cites this paper
• A comprehensive approach to lung function in bronchiectasis.

  2018cites this paper
• Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD

  2018cites this paper
• Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide

  2018cites this paper
• Utility and effectiveness of Symbicort® Turbuhaler® (oral inhalation containing budesonide and formoterol) in a patient with severe asthma after permanent tracheostomy

  2018cites this paper
• Using ion-pairs to modify salbutamol delivery to the lungs

  2018cites this paper
• University of Dundee A comprehensive approach to lung function in bronchiectasis Radovanovic,

  2018cites this paper
• Management of severe COPD exacerbations: focus on beclomethasone dipropionate/ formoterol/glycopyrronium bromide

  2018cites this paper
• Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD

  2017cites this paper
• Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease

  2017cites this paper
• Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.

  2017cites this paper
• Predicting treatable traits for long-acting bronchodilators in patients with stable COPD

  2017cites this paper
• Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

  2017cites this paper
• The evidence on tiotropium bromide in asthma: from the rationale to the bedside

  2017cites this paper
• Striving for optimal bronchodilation: focus on olodaterol

  2016cites this paper
• Cost-effectiveness of treatments for COPD

  2016cites this paper
• Cost-effectively prescribing treatments for managing COPD

  2016cites this paper
• Comparing the range and costs of COPD treatments in primary care

  2016cites this paper
• Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

  2016cites this paper
• A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler.

  2015cites this paper